New  ||| S:0 E:4 ||| JJ
approaches  ||| S:4 E:15 ||| NNS
to  ||| S:15 E:18 ||| TO
the  ||| S:18 E:22 ||| DT
prevention  ||| S:22 E:33 ||| NN
of  ||| S:33 E:36 ||| IN
childhood  ||| S:36 E:46 ||| NN
atopic  ||| S:46 E:53 ||| NNS
dermatitis  ||| S:53 E:64 ||| VBP
There  ||| S:64 E:70 ||| EX
has  ||| S:70 E:74 ||| VBZ
been  ||| S:74 E:79 ||| VBN
a  ||| S:79 E:81 ||| DT
steep  ||| S:81 E:87 ||| JJ
rise  ||| S:87 E:92 ||| NN
in  ||| S:92 E:95 ||| IN
the  ||| S:95 E:99 ||| DT
burden  ||| S:99 E:106 ||| NN
of  ||| S:106 E:109 ||| IN
atopic  ||| S:109 E:116 ||| JJ
dermatitis  ||| S:116 E:127 ||| NNS
( ||| S:127 E:128 ||| -LRB-
AD ||| S:128 E:130 ||| NNP
) ||| S:130 E:131 ||| -RRB-
,  ||| S:131 E:133 ||| ,
and  ||| S:133 E:137 ||| CC
up  ||| S:137 E:140 ||| RB
to  ||| S:140 E:143 ||| TO
20 ||| S:143 E:145 ||| CD
%  ||| S:145 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
children  ||| S:150 E:159 ||| NNS
in  ||| S:159 E:162 ||| IN
developed  ||| S:162 E:172 ||| JJ
countries  ||| S:172 E:182 ||| NNS
now  ||| S:182 E:186 ||| RB
suffer  ||| S:186 E:193 ||| VB
of  ||| S:193 E:196 ||| IN
the  ||| S:196 E:200 ||| DT
disease ||| S:200 E:207 ||| NN
.  ||| S:207 E:209 ||| .
At  ||| S:209 E:212 ||| IN
present ||| S:212 E:219 ||| JJ
,  ||| S:219 E:221 ||| ,
treatment  ||| S:221 E:231 ||| NN
at  ||| S:231 E:234 ||| IN
best  ||| S:234 E:239 ||| JJS
achieves  ||| S:239 E:248 ||| JJ
symptom  ||| S:248 E:256 ||| NN
control  ||| S:256 E:264 ||| NN
rather  ||| S:264 E:271 ||| RB
than  ||| S:271 E:276 ||| IN
cure ||| S:276 E:280 ||| NN
,  ||| S:280 E:282 ||| ,
and  ||| S:282 E:286 ||| CC
there  ||| S:286 E:292 ||| EX
is  ||| S:292 E:295 ||| VBZ
a  ||| S:295 E:297 ||| DT
strong  ||| S:297 E:304 ||| JJ
need  ||| S:304 E:309 ||| NN
to  ||| S:309 E:312 ||| TO
identify  ||| S:312 E:321 ||| VB
new  ||| S:321 E:325 ||| JJ
methods  ||| S:325 E:333 ||| NNS
of  ||| S:333 E:336 ||| IN
disease  ||| S:336 E:344 ||| NN
prevention ||| S:344 E:354 ||| NN
.  ||| S:354 E:356 ||| .
While  ||| S:356 E:362 ||| IN
earlier  ||| S:362 E:370 ||| JJR
approaches  ||| S:370 E:381 ||| NNS
focused  ||| S:381 E:389 ||| VBN
on  ||| S:389 E:392 ||| IN
allergen  ||| S:392 E:401 ||| JJ
avoidance  ||| S:401 E:411 ||| NN
strategies ||| S:411 E:421 ||| NNS
,  ||| S:421 E:423 ||| ,
there  ||| S:423 E:429 ||| EX
has  ||| S:429 E:433 ||| VBZ
been  ||| S:433 E:438 ||| VBN
a  ||| S:438 E:440 ||| DT
clear  ||| S:440 E:446 ||| JJ
shift  ||| S:446 E:452 ||| NN
towards  ||| S:452 E:460 ||| IN
attempts  ||| S:460 E:469 ||| NNS
to  ||| S:469 E:472 ||| TO
induce  ||| S:472 E:479 ||| VB
tolerance  ||| S:479 E:489 ||| NN
and  ||| S:489 E:493 ||| CC
enhancement  ||| S:493 E:505 ||| NN
of  ||| S:505 E:508 ||| IN
skin  ||| S:508 E:513 ||| NN
barrier  ||| S:513 E:521 ||| NN
function ||| S:521 E:529 ||| NN
,  ||| S:529 E:531 ||| ,
as  ||| S:531 E:534 ||| IN
skin  ||| S:534 E:539 ||| NN
barrier  ||| S:539 E:547 ||| NN
breakdown  ||| S:547 E:557 ||| NN
plays  ||| S:557 E:563 ||| VBZ
an  ||| S:563 E:566 ||| DT
important  ||| S:566 E:576 ||| JJ
role  ||| S:576 E:581 ||| NN
in  ||| S:581 E:584 ||| IN
AD  ||| S:584 E:587 ||| NNP
development ||| S:587 E:598 ||| NN
.  ||| S:598 E:600 ||| .
This  ||| S:600 E:605 ||| DT
article  ||| S:605 E:613 ||| NN
reviews  ||| S:613 E:621 ||| VBZ
the  ||| S:621 E:625 ||| DT
latest  ||| S:625 E:632 ||| JJS
developments  ||| S:632 E:645 ||| NNS
in  ||| S:645 E:648 ||| IN
the  ||| S:648 E:652 ||| DT
prevention  ||| S:652 E:663 ||| NN
of  ||| S:663 E:666 ||| IN
AD ||| S:666 E:668 ||| NNP
.  ||| S:668 E:670 ||| .
